文献速递冠心病心力衰竭与心肌病

微血管阻力储备与心血管结局:FLOW-CMD注册研究

Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry.
PubMed 文献 · Eur Heart J · 2026-08-28

FLOW-CMD前瞻性多中心注册研究纳入1003例接受侵入性冠脉造影的疑似缺血性心脏病患者,以MRR≤2.5定义冠脉微血管功能障碍。33.3%患者存在该障碍,中位随访1.9年时其主要复合终点风险显著升高(18.2% vs 8.6%,HR 1.94),多因素校正后仍独立相关(aHR 1.78)。

要点

  • MRR≤2.5定义的冠脉微血管功能障碍见于约三分之一造影患者。
  • 该障碍与全因死亡、心梗、重复血运重建或心衰住院复合终点风险升高相关。
  • MRR作为连续变量每降低1单位,主要终点风险增加16%。

核心结论

  • 在疑似缺血性心脏病接受侵入性冠脉造影的患者中,MRR≤2.5定义的冠脉微血管功能障碍见于三分之一患者,并与主要复合终点风险升高独立相关。

研究设计与样本

  • 前瞻性、多中心FLOW-CMD注册研究,连续纳入1003例接受临床指征侵入性冠脉造影并完成全面冠脉生理学评估的疑似缺血性心脏病患者。

主要发现

  • 334/1003例(33.3%)存在MRR≤2.5定义的冠脉微血管功能障碍。
  • MRR作为连续变量与主要终点风险相关(每降低1单位HR 1.16,95%CI 1.03-1.32,P=0.026)。
  • 中位随访1.9年,主要终点在微血管功能障碍组发生47/334例(18.2%),微血管功能保留组49/669例(8.6%)(HR 1.94,95%CI 1.30-2.90,P=0.001)。
  • 多因素分析中MRR≤2.5定义的冠脉微血管功能障碍与主要终点独立相关(校正HR 1.78,95%CI 1.06-2.99,P=0.030)。

关键数值与推荐

  • 冠脉微血管功能障碍定义为任一评估血管MRR≤2.5。
  • 主要终点为全因死亡、心肌梗死、临床驱动的重复血运重建或心衰住院的复合终点。

临床怎么用

  • 对接受侵入性冠脉造影的疑似缺血性心脏病患者,可考虑测量MRR以识别冠脉微血管功能障碍高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Microvascular resistance reserve (MRR) is a novel index for assessing coronary microvascular function that is independent of epicardial coronary artery stenosis and subtended myocardial mass. However, limited data are available regarding the clinical relevance of coronary microvascular dysfunction, defined by MRR in patients undergoing clinically indicated invasive coronary angiography. This study sought to evaluate the incidence and prognostic impact of coronary microvascular dysfunction defined by MRR in routine practice. METHODS: In the prospective, multicentre FLOW-CMD Registry, 1003 consecutive patients with suspected ischaemic heart disease who underwent clinically indicated invasive coronary angiography with comprehensive coronary physiologic assessment were prospectively enrolled. Coronary microvascular dysfunction was defined as MRR ≤2.5 in any evaluated vessel. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularisation, or hospitalisation for heart failure. RESULTS: Coronary microvascular dysfunction was identified in 334 of 1003 patients (33.3%). MRR as a continuous variable was associated with the risk of the primary endpoint (hazard ratio [HR] per 1-unit decrease, 1.16; 95% confidence interval [CI] 1.03-1.32; P=0.026). At a median follow-up of 1.9 years, the primary endpoint occurred in 47 of 334 patients (18.2%) with coronary microvascular dysfunction and 49 of 669 patients (8.6%) with preserved microvascular function (HR 1.94; 95% CI 1.30-2.90; P=0.001). On multivariable analysis, coronary microvascular dysfunction defined by MRR ≤2.5 was independently associated with the primary endpoint (adjusted HR 1.78; 95% CI 1.06-2.99; P=0.030). CONCLUSIONS: In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction defined by MRR ≤2.5 was observed among one-third of patients, and was associated with an increased risk of a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularisation, or hospitalisation for heart failure (Multicenter FLOW-CMD Registry ClinicalTrials.gov number, NCT05369182).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lee SH, Ahn JH, Jones WS, et al. Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry. Eur Heart J. 2026. PMID: 42661450. doi:10.1093/eurheartj/ehag705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。